Leipzig, Germany, November 29 (ots/PRNewswire) - - Ophthalmic Clinic in Germany First in Europe To Treat Patients With New Focused Radiation Therapy NeoVista, Inc. announced today that the first European patient has been treated in the company's pivotal global clinical trial for its novel beta radiation epiretinal therapy for the wet form of age-related ...
Hoofddorp, The Netherlands, November 27 (ots/PRNewswire) - On Thursday November 29, at 14:00 CET, CEVA's Chief Executive Officer John Pattullo and its Chief Financial Officer Stuart Young will present CEVA's third quarter 2007 results. After the presentation CEVA's CEO and CFO will answer questions. Bondholders, analysts and potential investors are invited to ...
Collegeville, Pennsylvania, November 26 (ots/PRNewswire) - - TORISEL Extends Median Overall Survival vs. Interferon-Alpha Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that the European Commission has approved TORISEL(TM) (temsirolimus) for the first-line treatment of patients ...
Toronto, November 22 (ots/PRNewswire) - "CBM urgently needs help for the most vulnerable people affected by the recent flooding in Bangladesh," says Prof. Allen Foster President of CBM. The latest report says the death toll in the fiercest cyclone to hit Bangladesh's southern and southwestern coastal area in over 130 years has climbed to over 2,300. "Our staff and partners on the ground are reporting that many people with disabilities living in poverty are ...
Basel, Switzerland, November 20 (ots/PRNewswire) - - Annals of Oncology Paper Suggests That Oral Agents Such as Xeloda, Which are Proven to be Equally Effective and Have a Tolerable Side Effect Profile, Should Replace Traditional Intravenous Chemotherapy A review paper in Annals of Oncology now ...
Amsterdam, November 19 (ots/PRNewswire) - Kiadis Pharma announced today that it has agreed to provide Rhitol during a limited period of time to requesting physicians participating in the ongoing phase I/II trial. The Rhitol phase I/II trial is closed for enrolment to treat new patients and is expected to complete ...
Basel, Switzerland, November 16 (ots/PRNewswire) - - Avastin Offers Patients the Chance to Live Twice as Long Without Their Disease Advancing Roche announced today that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for Avastin (bevacizumab) for ...
Bill & Melinda Gates Foundation
Seattle, November 14 (ots/PRNewswire) - - New initiative to support prevention programs targeting high-risk groups The Bill & Melinda Gates Foundation announced today that it will commit US$50 million to work in partnership with the Chinese government and non-governmental organizations to expand HIV prevention efforts in China. The funding will increase ...
Freising-Weihenstephan (ots) - Pieris AG, a biopharmaceutical company developing Anticalins®, a novel class of targeted human protein therapeutics, today announced the appointment of Dr Angelika Stern as Chief Operating Officer to the Company. Pieris has also announced the promotion with immediate effect of ...
Beijing, November 8 (ots/PRNewswire) - - Research Shows the New Test is Accurate, Simple to Run and Requires Minimal Resources Research demonstrating the potential of a special type of HPV test developed by QIAGEN with support from PATH -- a non-profit global health organization -- to reduce the incidence ...
Basel, Switzerland, November 7 (ots/PRNewswire) - - TOWARD Study, Presented at Major US Congress ACR, Confirms IL-6 Receptor Inhibition Plays a Key Role in the Treatment of RA The innovative new rheumatoid arthritis drug Actemra (tocilizumab) has been shown to significantly improve the signs and symptoms of rheumatoid arthritis (RA) in patients who failed to ...
NHMRC Clinical Trials Centre - The University of Sydney
Sydney, November 7 (ots/PRNewswire) - In the Lancet, on Tuesday November, 6th new results of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) 2007 clinical trial have been published and presented on the same date at a press conference held during the AHA. - First lipid modifying agent shown to reduce the need for treatment of the leading ...
Shire Pharmaceuticals Group Plc
Philadelphia and Basingstoke, England, November 6 (ots/PRNewswire) - Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) today announced the results of a Phase II study indicating that FOSRENOL can effectively reduce serum phosphate levels in chronic kidney disease (CKD) patients not on dialysis.(1) FOSRENOL is a non-calcium phosphate binder, indicated to treat ...
Lyon, France, November 6 (ots/PRNewswire) - Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced today positive results in the development of a vaccine for the global prevention of dengue fever, one of the most widespread tropical diseases. The results are being presented today at the American Society of Tropical Medicine and Hygiene (ASTMH)'s ...
NHMRC Clinical Trials Centre - The University of Sydney
Sydney, November 6 (ots/PRNewswire) - - First Lipid Modifying Agent Shown to Reduce Risk of Leading Causes of Blindness and Deteriorating Vision in Patients With Type 2 Diabetes - Reduces Need for Laser Treatment in Patients With and Without Known Diabetic Retinopathy - Significantly Decreases Progression of Diabetic Eye Disease Fenofibrate is the ...
Orlando, Florida, November 5 (ots/PRNewswire) - Resverlogix Corp. ("Resverlogix") (TSX:RVX) is pleased to announce today key scientific data was presented in an oral presentation highlighting the novel features of RVX-208, at the American Heart Association Scientific Meetings. The presentation titled "Oral ...
Shire Pharmaceuticals Group Plc
Basingstoke, England, November 5 (ots/PRNewswire) - - For global distribution excluding the US and Canada New data presented today at the 40th annual American Society of Nephrology (ASN) meeting and scientific exposition in San Francisco, CA, USA, show that epoetin delta - the only erythropoiesis-stimulating agent (ESA) produced in a human cell line - has ...
Basel, Switzerland, November 5 (ots/PRNewswire) - -Low Haemoglobin Levels Associated With Increased Risk of Cardiovascular Disease and Death Data from the analysis of six major trials for the innovative new renal anaemia treatment MIRCERA, have shown that it effectively corrects and maintains haemoglobin ...
Tokyo and Indianapolis, November 4 (ots/PRNewswire) - - Duke Clinical Research Institute to lead multinational study with investigational compound; will include 10,000 medically managed patients with acute coronary syndrome A large Phase III clinical trial is anticipated to begin in the second quarter of 2008 to compare the effects of prasugrel, ...
Tokyo and Indianapolis, November 4 (ots/PRNewswire) - - Investigational compound reduces risk of major cardiovascular events by 19 percent, significantly improves net clinical benefit despite increased bleeding In the pivotal Phase III head-to-head TRITON TIMI-38 clinical trial, the investigational ...
Boston, November 2 (ots/PRNewswire) - - This Landmark Study Also Shows Response at 12 Weeks is a Powerful Predictor of Eventual Treatment Success. Roche today announced final results from the REPEAT study, which demonstrate that treatment with once-weekly PEGASYS(R) (peginterferon alfa-2a(40KD)) and ...
Basel, Switzerland, November 2 (ots/PRNewswire) - - Roche Progresses R1626 Into Phase IIb Study Called POLI 1 R1626, one of Roche's new investigational drugs for hepatitis C (HCV), has shown promising antiviral efficacy when given in combination with PEGASYS(R) (peginterferon alfa-2a (40KD)) and COPEGUS(R) (ribavirin), according to results being presented at ...
Brussels (ots/PRNewswire) - First study to investigate the protective effect of a lipid-lowering agent on diabetic eye disease to be published on-line in Lancet, Tuesday, 6th November 2007 Diabetic eye disease (called diabetic retinopathy) is the leading cause of vision loss in adults - affecting about 25 ...
Paris (ots/PRNewswire) - - Novel Compound Offers Hope to Patients not Adequately Responding to Laxative Treatment Data presented for the first time today at the international gastroenterology meeting UEGW (United European Gastroenterology Week) confirm the effectiveness and safety of RESOLOR(R) ...
Lugano (ots) - Oral Formulations of 5-HT3 receptor Antagonists Represent Approximately 10% of the Day-of-Chemotherapy Market - Helsinn Healthcare SA, a privately owned Swiss pharmaceutical group, and its partner MGI PHARMA, INC., (Nasdaq: MOGN), a biopharmaceutical company focused in oncology and acute care, ...
Irvine, California (ots/PRNewswire) - IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that, at the special meeting of stockholders re-convened earlier today, IsoTis stockholders have approved the acquisition of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an agreement and plan of merger dated as of August 6, 2007. The acquisition is ...
Toronto (ots/PRNewswire) - Dalton Medicinal Chemistry Partners, the Medicinal Chemistry arm of Dalton Pharma Services, announces that it has achieved a targeted milestone in its Medicinal Chemistry agreement with Boehringer Ingelheim (Canada) Ltd. The milestone achievement triggered payment of an undisclosed ...
Basel, Switzerland (ots/PRNewswire) - A new study on pain published today has found that subcutaneous (SC) injections of the new renal anaemia therapy MIRCERA is associated with significantly less pain immediately after injection than SC darbepoetin-alfa (Aranesp).(1) These findings are important because to date there has been minimal data regarding SC injection ...
Irvine, California (ots/PRNewswire) - - Less Than 40,000 Additional "FOR" Votes Required for Integra Merger IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today announced that it has adjourned its special meeting of stockholders again, to Monday, October 29, 2007, to approve the acquisition of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an ...
Irvine, California (ots/PRNewswire) - - Less than 100,000 Additional "FOR" Votes Required for Integra Merger IsoTis, Inc. (NASDAQ: ISOT) ("IsoTis"), an orthobiologics company, today reported that less than 100,000 votes "FOR" are needed to approve the acquisition of IsoTis by Integra LifeSciences Holdings Corporation (NASDAQ: IART) ("Integra") pursuant to an agreement and plan of merger dated as of August 6, ...